This activity is supported by an independent educational grant from Novartis Pharmaceuticals Corporation.
On-demand CE Webinar
Karol Harshaw-Ellis, MSN, DNP, A/GNP, ACNP
Cardiology Nurse Practitioner
Heart Failure Disease Management Program
Director of Outreach
Same Day Access Clinic
Duke University Health System
This on-demand webinar will provide nurse practitioners with up-to-date information on how to manage patients with heart failure (HF), including adherence techniques, safety and efficacy of the most recently approved pharmacotherapies, and strategies to reduce hospitalization. This on-demand webinar will also discuss the role of nurse practitioners in the prevention and treatment of heart failure.
At the completion of this activity, the participant will be able to:
Statement of Need: Patients with heart failure (HF), who have comorbid conditions are often initially managed and treated by primary healthcare providers, such as nurse practitioners (NPs). Due to the rising prevalence of HF, the economic burden, and the high-risk of mortality, it is critical that NPs are up-to-date on the most recent prevention and management guidelines, and are aware of the safety and efficacy of recently approved pharmacotherapies for HF to optimize patient outcomes.
Targeted Audience: Nurse Practitioners
Length of Webinar: 1 hour
Release Date: April 18, 2018
Expiration Date: October 18, 2018
How to Obtain Credit
To receive credit, participants must complete the online pretest, view the activity in its entirety, and complete the online post-test and activity evaluation form. After completing the online assessment tests, and completing the activity evaluation form, participants may request credit. All participants must request credit before October 18, 2018. CE credit will not be issued after this date.
Identify patients with cardiometabolic disease who are at risk for HF
Articulate the role of the nurse practitioner in the prevention and treatment of HF
Summarize the 2016 American College of Cardiology/American Heart Association/Heart Failure Society of America (ACC/AHA/HFSA) guideline update on new pharmacological therapies for HF
Evaluate the mechanisms of action, pharmacologic features, and dosing of existing and new agents for treating and managing HF
Describe how to implement strategies that may reduce hospitalization and readmission, such as adherence to therapy, appropriate discharge instructions, and a collaborative team-based approach to patient care
This activity is jointly provided by Global Education Group and Physicians’ Education Resource®
, LLC (PER®).
Global Education Group is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners: AANP Provider Number 110121. This program has been approved for 1.0 contact hours of continuing education (which includes 0.2hours of pharmacology). Activity ID#
This activity was planned in accordance with AANP CE Standards and Policies.
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Karol Harshaw-Ellis, MSN, DNP, A/GNP, ACNP has the following relevant financial relationships with commercial interest to disclose:
The following contributors have no relevant financial relationships with commercial interests to disclose.
Physicians’ Education Resource®, LLC (PER®).
Planning Staff—David Heckard; Maryjo Dixon, RPh; Donna Fausak
Global Education Group
Advisory Board: Novartis Pharmaceuticals Corporation
Kristin Delisi, NP, Lindsay Borvansky, Liddy Knight, Andrea Funk
Acknowledgement of Commercial Support:
This activity is supported by an educational grant from Novartis.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and
Physicians’ Education Resource®
, LLC (PER®) do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Required: Windows® 7, Vista, XP, 2003 Server or 2000
Required: Mac OS® X 10.4.11 (Tiger®) or newer
For questions about this Internet activity, please contact: firstname.lastname@example.org